Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients

Liver Transplantation

Volumn 9, Issue 2, 2003, Pages 126-129

  Nair, Satheesh ^a   Eason, James ^a   Loss, George ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; FENOFIBRATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; TACROLIMUS; UREA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; MOUTH ULCER; NEPHROTOXICITY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

EID: 0037322466     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50026     Document Type: Article

References (12)

1. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781-789.
2. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
3. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal insufficiency following liver transplantation: A retrospective analysis. Transplantation 1998;66:59-66.
4. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001;72:1934-1939.
5. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
6. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58:170-178.
7. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001;7(suppl 1):S22-S26.
8. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (sirolimus)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-1042.
9. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, et al. Experience with the use of sirolimus in liver transplantation-Use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000;6:734-740.
10. Kahan BD, Stepkowski SM, Napoli KL, Katz SM, Knight RJ, Van Buren C. The development of sirolimus: The University of Texas-Houston experience. Clin Transpl 2000:145-158.
11. Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001;38(suppl 2):S16-S21.
12. Crawford DH, Endre ZH, Axelsen RA, Lynch SV, Balderson GA, Strong RW, et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992;19:339-344.